Suppr超能文献

常见可变免疫缺陷症的健康政策:疾病负担。

Health policy for common variable immunodeficiency: burden of the disease.

机构信息

Research Center for Immunodeficiencies, Pediatrics Center of Excellence, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran.

出版信息

J Investig Allergol Clin Immunol. 2011;21(6):454-8.

Abstract

BACKGROUND

Common variable immunodeficiency (CVID) is a primary immunodeficiency disease characterized by recurrent infections and increased susceptibility to autoimmunity and malignancy.

OBJECTIVES

This study was performed to estimate the burden of CVID in Iran during 1985-2008 based on incidence, mortality, and disability-adjusted life-years (DALY).

METHODS

The methods developed by the World Health Organization for national burden of disease studies were applied to estimate the incidence of disease and thus calculate the years of life lost due to premature mortality (YLL), years living with disability (YLD), and DALYs.

RESULTS

The average age-adjusted incidence of CVID was 1 case per 200 000 per year; the average age-adjusted prevalence was 1 case per 91 000 per year. The burden of CVID (DALYs) was 25.21 years per 100000 individuals (17.86 for YLL and 7.35 for YLD). DALYs increased significantly in patients aged 5-14 years and in those with polyclonal lymphocytic infiltration phenotypes (P < .001).

CONCLUSIONS

Based on the measurement of DALY in patients with CVID, reducing the rate of premature death in the polyclonal lymphocytic infiltration phenotype and the rate of infectious episodes in patients with the infectious only phenotype and appropriate management with regular intravenous immunoglobulin represent the best approach to decreasing the burden of CVID.

摘要

背景

普通变异性免疫缺陷(CVID)是一种以反复感染和增加自身免疫及恶性肿瘤易感性为特征的原发性免疫缺陷病。

目的

本研究旨在根据发病率、死亡率和伤残调整生命年(DALY)来评估 1985 年至 2008 年期间伊朗的 CVID 负担。

方法

应用世界卫生组织用于国家疾病负担研究的方法来估计疾病的发病率,从而计算因过早死亡导致的生命年损失(YLL)、残疾生存年(YLD)和 DALY。

结果

平均年龄校正后的 CVID 发病率为每年每 200000 人中有 1 例;平均年龄校正后的患病率为每年每 91000 人中有 1 例。CVID 的负担(DALY)为每 100000 人 25.21 年(17.86 年用于 YLL,7.35 年用于 YLD)。5-14 岁患者和多克隆淋巴细胞浸润表型患者的 DALY 显著增加(P<0.001)。

结论

根据 CVID 患者的 DALY 测量,减少多克隆淋巴细胞浸润表型患者的过早死亡率和仅感染表型患者的感染发作率,并通过定期静脉注射免疫球蛋白进行适当管理,是降低 CVID 负担的最佳方法。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验